{"nctId":"NCT00442936","briefTitle":"Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)","startDateStruct":{"date":"2007-02-15","type":"ACTUAL"},"conditions":["Migraine"],"count":1380,"armGroups":[{"label":"Telcagepant 150 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Telcagepant potassium 150 mg","Drug: Placebo to tecagepant 300 mg","Drug: Placebo to zolmitriptan 5 mg","Drug: Rescue medication"]},{"label":"Telcagepant 300 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Telcagepant potassium 300 mg","Drug: Placebo to telcagepant 150 mg","Drug: Placebo to zolmitriptan 5 mg","Drug: Rescue medication"]},{"label":"Zolmitriptan 5 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Zolmitriptan 5 mg","Drug: Placebo to telcagepant 150 mg","Drug: Placebo to tecagepant 300 mg","Drug: Rescue medication"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo to telcagepant 150 mg","Drug: Placebo to tecagepant 300 mg","Drug: Placebo to zolmitriptan 5 mg","Drug: Rescue medication"]}],"interventions":[{"name":"Telcagepant potassium 150 mg","otherNames":[]},{"name":"Telcagepant potassium 300 mg","otherNames":[]},{"name":"Zolmitriptan 5 mg","otherNames":[]},{"name":"Placebo to telcagepant 150 mg","otherNames":[]},{"name":"Placebo to tecagepant 300 mg","otherNames":[]},{"name":"Placebo to zolmitriptan 5 mg","otherNames":[]},{"name":"Rescue medication","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has at least 1 year history of migraine (with or without aura)\n* Females of child bearing potential must use acceptable contraception throughout trial.\n\nExclusion Criteria:\n\n* Is pregnant/breast-feeding (or is a female expecting to conceive during study period)\n* Has history or evidence of stroke/transient ischemic attacks, heart disease, coronary artery vasospasm, other significant underlying cardiovascular diseases, uncontrolled hypertension (high blood pressure), uncontrolled diabetes, or human immunodeficiency virus (HIV) disease\n* Has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other than migraine)\n* Has a history of gastric, or small intestinal surgery, or has a disease that causes malabsorption\n* Has a history of cancer within the last 5 years.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Pain Freedom (PF) at 2 Hours Post-Dose","description":"Participants were asked to rate their migraine headache severity with ratings of 0=No pain, 1=Mild pain, 2=Moderate pain, and 3=Severe pain. PF at 2 hours post-dose is defined as a decrease from a moderate or severe migraine headache (Grade 2 or 3) at baseline to no pain (Grade 0) at 2 hours post-dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"89","spread":null},{"groupId":"OG002","value":"101","spread":null},{"groupId":"OG003","value":"29","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Pain Relief (PR) at 2 Hours Post-Dose","description":"Participants were asked to rate their migraine headache severity with ratings of 0=No pain, 1=Mild pain, 2=Moderate pain, and 3=Severe pain. PR at 2 hours post-dose is defined as a shift from a moderate or severe migraine headache (Grade 2 or 3) at baseline to mild or no pain (Grade 1 or 0) at 2 hours post-dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"183","spread":null},{"groupId":"OG002","value":"185","spread":null},{"groupId":"OG003","value":"88","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Absence of Photophobia at 2 Hours Post-Dose","description":"Participants were asked if they experienced any sensitivity to light. The number of participants who experienced no photophobia (sensitivity to light) at 2 hours post-dose was determined.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"169","spread":null},{"groupId":"OG002","value":"163","spread":null},{"groupId":"OG003","value":"92","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Absence of Phonophobia at 2 Hours Post-Dose","description":"Participants were asked if they experienced any sensitivity to sound. The number of participants who experienced no phonophobia (sensitivity to sound) at 2 hours post-dose was determined.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"170","spread":null},{"groupId":"OG001","value":"193","spread":null},{"groupId":"OG002","value":"180","spread":null},{"groupId":"OG003","value":"120","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Absence of Nausea at 2 Hours Post-Dose","description":"Participants were asked if they experienced any nausea. The number of participants who experienced no nausea at 2 hours post-dose was determined.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"212","spread":null},{"groupId":"OG001","value":"218","spread":null},{"groupId":"OG002","value":"232","spread":null},{"groupId":"OG003","value":"179","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Sustained Pain Freedom (SPF) From 2 to 24 Hours Post-Dose","description":"SPF is defined as PF at 2 hours post-dose with no return of mild/moderate/severe headache through 24 hours post-dose, and with no administration of either the optional second dose of study drug or any rescue medication between 2 and 24 hours post-dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"66","spread":null},{"groupId":"OG002","value":"59","spread":null},{"groupId":"OG003","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Total Migraine Freedom (TMF) at 2 Hours Post-Dose","description":"TMF at 2 hours post-dose is defined as PF at 2 hours post-dose without any of the following migraine-related symptoms: phonophobia, photophobia, nausea or vomiting at 2 hours post-dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"76","spread":null},{"groupId":"OG002","value":"87","spread":null},{"groupId":"OG003","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Total Migraine Freedom (TMF) at 2 to 24 Hours Post-Dose","description":"TMF at 2 to 24 hours post-dose is defined as TMF at 2 hours post-dose with no administration of either the optional second dose of study drug or any rescue medication between 2 and 24 hours post-dose, no return of mild/moderate/severe headache within 24 hours and no presence of phonophobia, photophobia, nausea or vomiting within 24 hours post-dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"57","spread":null},{"groupId":"OG002","value":"51","spread":null},{"groupId":"OG003","value":"13","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Experience At Least One Adverse Event (AE)","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Participants were monitored for occurrence AEs for up to 14 days after last dose study drug. Participants who took both active and placebo study drug were counted in the active group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"131","spread":null},{"groupId":"OG002","value":"175","spread":null},{"groupId":"OG003","value":"112","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Discontinue Study Drug Due to an AE","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Participants who took both active and placebo study drug were counted in the active group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":334},"commonTop":["Dizziness","Dry mouth","Somnolence","Nausea","Fatigue"]}}}